Skip Navigation

QJM 2007 100(5):253-262; doi:10.1093/qjmed/hcm025
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yanai, H.
Right arrow Articles by Tada, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanai, H.
Right arrow Articles by Tada, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Atherosclerosis imaging in statin intervention trials

H. Yanai1, H. Yoshida1,2, Y. Tomono3 and N. Tada1

From the Departments of 1Internal Medicine, and 2Laboratory Medicine, The Jikei University School of Medicine, Kashiwa, Japan, and 3Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan

Address correspondence to Dr H. Yanai, Department of Internal Medicine, Kashiwa Hospital, The Jikei University School of Medicine, Chiba 277-8567, Japan. email: yanaih@jikei.ac.jp

The first 150 words of the full text of this article appear below.


   Introduction
 
Cardiovascular diseases are the principal causes of mortality in middle-aged and older people worldwide. Coronary heart disease (CHD) is the most common cardiovascular disease, and atherosclerosis is considered its most important cause. Epidemiological, clinical, and experimental evidence suggests that high serum cholesterol is associated with atherosclerosis.1 Several large randomized controlled studies of statins (drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A, or HMG-CoA) have demonstrated a clear reduction in the incidence of coronary events, in patients either with or without previous CHD.2–5 Because atherosclerosis progresses over decades, intervention trials require long-term follow-up and a large number of participants. To assess modifiers of atherosclerotic disease progression such as statins or lifestyle, surrogate markers are often needed to investigate determinants of atherosclerosis. Validated surrogate markers enable the assessment of promising new drugs in a relatively short period of time, thus avoiding the need to await the outcome of trials driven by clinical events. If more . . . [Full Text of this Article]


   Non-invasive evaluation of atherosclerosis by monitoring blood pressure or pulse
 

   Non-invasive evaluation of atherosclerosis by ultrasound monitoring atherosclerosis imaging
 

   Non-invasive evaluation of atherosclerosis preformed by monitoring magnetic resonance imaging (MRI)
 

   Non-invasive evaluation of atherosclerosis using computed tomography (CT)
 

   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?